The DOI matches its Crossref record.
Poly(ADP-Ribose) Polymerase Inhibitors
Abstract
Poly(ADP-ribose) polymerase-1 (PARP-1) is the principal member of the PARP enzyme family consisting of PARP-1 and several recently identified novel poly(ADP-ribosyl)ating enzymes. PARP-1 functions as a DNA damage sensor and signalling molecule. Upon binding to DNA breaks, activated PARP cleaves NAD(+) into nicotinamide and ADP-ribose and polymerizes the latter onto nuclear acceptor proteins including histones, transcription factors and PARP itself. This Poly(ADP-ribosyl)ation contributes to inflammatory signal transduction processes. In addition, oxidative stress-induced overactivation of PARP consumes NAD(+) and consequently ATP, culminating in cell dysfunction or necrosis. Activation of PARP has been implicated in the pathogenesis of stroke, myocardial ischemia, diabetes, diabetes-associated cardiovascular dysfunction, shock, traumatic central nervous system injury, arthritis, colitis, allergic encephalomyelitis and various other forms of inflammation. Therefore, inhibition of PARP by pharmacological agents may prove useful for the therapy of these diseases, as has been shown in preclinical animal models. Moreover, PARP inhibitors may have additional, potential utility as anticancer agents, radiosensitizers and antiviral agents. In the present article we overview the structures and pharmacological actions of various pharmacological classes of compounds which inhibit the catalytic activity of PARP.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs
Gibson, B. A., & Kraus, W. L. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3376 · Cited by 1,226
Increased Nuclear NAD Biosynthesis and SIRT1 Activation Prevent Axonal Degeneration
Araki, T., Sasaki, Y., & Milbrandt, J. (2004) · Science · doi:10.1126/science.1098014 · Cited by 1,060
Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors
Jagtap, P., & Szabó, C. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1718 · Cited by 896
Self-citationDiabetic neuropathy: Mechanisms to management
Edwards, J. L., Vincent, A. M., Cheng, H. T., & Feldman, E. L. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.05.005 · Cited by 790
Kraus, W. L., & Lis, J. T. (2003) · Cell · doi:10.1016/s0092-8674(03)00433-1 · Cited by 546
Evolution of Poly(ADP-ribose) Polymerase-1 (PARP-1) Inhibitors. From Concept to Clinic
Ferraris, D. V. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100012m · Cited by 363
Koh, D. W., Lawler, A. M., Poitras, M. F., Sasaki, M., Wattler, S., Nehls, M. C., Stöger, T., Poirier, G. G., Dawson, V. L., & Dawson, T. M. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406182101 · Cited by 339
Pacher, P., & Szabó, C. (2007) · Cardiovascular Drug Reviews · doi:10.1111/j.1527-3466.2007.00018.x · Cited by 316
Self-citationNovel Agents on the Horizon for Cancer Therapy
Ma, W. W., & Adjei, A. A. (2009) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20003 · Cited by 304
Current Development of Clinical Inhibitors of Poly(ADP-Ribose) Polymerase in Oncology
Ratnam, K., & Low, J. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2260 · Cited by 286
Mechanisms of disease: The oxidative stress theory of diabetic neuropathy
Figueroa-Romero, C., Sadidi, M., & Feldman, E. L. (2008) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-008-9104-2 · Cited by 284
Poly(ADP‐ribose) polymerase in plants affects energy homeostasis, cell death and stress tolerance
Block, M. D., Verduyn, C., Brouwer, D. D., & Cornelissen, M. (2005) · The Plant Journal · doi:10.1111/j.1365-313x.2004.02277.x · Cited by 267
Metadata
- Authors
- Southan, G., & Szabó, C.
- Venue
- Current Medicinal Chemistry
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2003-02-01
- Volume
- 10
- Issue
- 4
- Pages
- 321-340
- ISSN
- 0929-8673 (ISSN-L)
- OpenAlex
- W2145577632
- Cited by
- 180
- References
- 0
- FWCI
- 10.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.